Lunai Bioworks Inc. cash flow to debt ratio of -77.40% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Lunai Bioworks Inc.'s free cash flow has increased -28.68% from $-11.04M last year to $-7.87M, signaling increasing performance

Lunai Bioworks Inc.'s debt to equity ratio is -0.15, signaling that the company spent its equity and risk bankruptcy.

Lunai Bioworks Inc.'s debt to equity ratio is -0.15, signaling that the company spent its equity and risk bankruptcy.

Lunai Bioworks Inc. has negative EBITDA, making leverage ratio unreliable

Lunai Bioworks Inc.'s interest coverage ratio is -16.23, which means that the company struggles to meet interest obligations, signaling financial risk.

Lunai Bioworks Inc. has insufficient data to evaluate this check.

Lunai Bioworks Inc.'s short-term liabilities of $29.16M exceed its short-term assets of $1.05M, signaling financial risk

Lunai Bioworks Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Lunai Bioworks Inc.'s return on equity of 892.52%, is higher than 15.00%, indicating good performance

Lunai Bioworks Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Lunai Bioworks Inc. has insufficient public price history to evaluate earnings stability.

Lunai Bioworks Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Lunai Bioworks Inc. has negative free cash flow, indicating cash burn

Lunai Bioworks Inc.'s yearly earnings has decreased 101.31% since last year from $-88.43M to $-178.01M, signaling decreasing performance

Lunai Bioworks Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC 120.87% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Lunai Bioworks Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Lunai Bioworks Inc. has insufficient public price history to evaluate revenue consistency.

Lunai Bioworks Inc. has insufficient public price history to evaluate ROE consistency.

Lunai Bioworks Inc. has insufficient data to evaluate this check.

Lunai Bioworks Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lunai Bioworks Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Lunai Bioworks Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Lunai Bioworks Inc. has insufficient data to evaluate this check.

Lunai Bioworks Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lunai Bioworks Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Lunai Bioworks Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue